Trump Executive Order On Drug Pricing Is A Mixed Bag For Pharma

Fast Followers May Win Quicker Path To Approval

 
• By Mandy Jackson
  
Small molecule developers could benefit from Trump's executive order but specifics are unclear (Shutterstock)

More from Drug Pricing

More from Market Access